NAMina Bio is building a translational architecture platform for human-relevant drug development. Our mission is to integrate New Approach Methodologies — into standardized workflows that help reduce reliance on poorly predictive animal models and improve preclinical decision-making.

The core problem is the predictive gap in drug development. Drug discovery is not failing because we lack biological tools. It is failing because many preclinical systems do not translate well into human outcomes.

This is the investment thesis. First, there is a massive market shift toward human-relevant translational models. Second, NAMina has unique positioning as an integration and decision layer, not a single-tool company.Third, the model is capital-efficient because we can generate early revenue through pilots, partner-enabled execution, and BioLabs Marketplace access. Fourth, the company is strategically aligned with regulatory momentum, pharma demand, and the growth of AI-driven biomedical research